0001562180-22-006580.txt : 20220909 0001562180-22-006580.hdr.sgml : 20220909 20220909160927 ACCESSION NUMBER: 0001562180-22-006580 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211101 FILED AS OF DATE: 20220909 DATE AS OF CHANGE: 20220909 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duker Jay S. CENTRAL INDEX KEY: 0001630864 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 221236303 MAIL ADDRESS: STREET 1: C/O ELEVEN BIOTHERAPEUTICS STREET 2: 215 1ST ST. #400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4/A 1 primarydocument.xml PRIMARY DOCUMENT X0306 4/A 2021-11-01 2021-11-03 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001630864 Duker Jay S. C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false Chief Operating Officer Stock Option (Right to Buy) 11.47 2021-11-01 4 A false 239700.00 0.00 A 2031-11-01 Common Stock 239700.00 239700.00 D The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. Due to an administrative error, the Reporting Person's previous Form 4 filed on November 3, 2021 incorrectly reported the Reporting Person receiving an option grant of 305,000 shares of common stock when it should have been reported as 239,700 shares of common stock. /s/ Ron Honig, Attorney-in-Fact 2022-09-09